Search - tctmd.com

Displaying 281 - 300 of 413

Sort: Relevancy | Date

News Conference News AHA 2013

French Registry: FFR Safely Reclassifies Almost Half of Revascularization Patients

Yael L. Maxwell

November 20, 2013

News Conference News TCT 2013

HYBRID: Hybrid Revascularization Shows Safety, Effectiveness vs. CABG in Multivessel CAD

October 31, 2013

News Conference News TCT 2013

Regulatory Hurdles Pose Challenges for Device Approvals in US, Europe

October 30, 2013

News Conference News TCT 2013

SYNTAX Cost-effectiveness Analysis Supports Existing Guidelines

October 29, 2013

Presentation TCT 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

A Synthesis of the Global Literature on TAVR Cost-effectiveness

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

Cost-Effectiveness of Catheter-Based Renal Denervation in Severe Treatment Resistant Hypertension

Presenter: Jan Pietzsch

October 27, 2013

Presentation TCT 2013

Cost-Effectiveness Considerations for Mild and Moderate Hypertension

Presenter: Mark Hlatky

October 27, 2013

News Daily News

Designation as ‘Unfit for Open Repair’ Predicts Worse EVAR Outcomes

Leah Lawrence

September 13, 2013

News Conference News ESC 2013

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

Yael L. Maxwell

September 03, 2013

News Daily News

FAME 2: FFR-Guided PCI ‘Economically Attractive’ vs. Medical Therapy Alone

Caitlin E. Cox

August 30, 2013

News Daily News

Ambulatory EVAR an Option for One-Third of AAA Patients

Yael L. Maxwell

August 30, 2013

Presentation

Cost-Effectiveness of PCI in Patients with Stable Coronary Disease and Abnormal Fractional Flow Reserve (FFR)

Presenter: William F. Fearon

August 23, 2013

News Daily News

Oral Sirolimus Appears to Augment Efficacy of BMS

Caitlin E. Cox

August 23, 2013

News Daily News

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

July 25, 2013

News Daily News

COURAGE: Medical Therapy ‘Crossovers’ Have More Symptoms, not More Hard Events

July 19, 2013

News Daily News

European TAVR Usage Tied to Economics, Reimbursement

Yael L. Maxwell

July 12, 2013

News Daily News

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

L.A. McKeown

July 05, 2013

Presentation TVT 2013

Cost-effectiveness of Surgical AVR vs. TAVR Using Registry Data

Presenter: Christopher Meduri

June 13, 2013

Presentation TVT 2013

TAVR Cost-effectiveness and Reimbursement: A Global Gordian Knot

Presenter: David Cohen

June 12, 2013

Advertisement

French Registry: FFR Safely Reclassifies Almost Half of Revascularization Patients

HYBRID: Hybrid Revascularization Shows Safety, Effectiveness vs. CABG in Multivessel CAD

Regulatory Hurdles Pose Challenges for Device Approvals in US, Europe

SYNTAX Cost-effectiveness Analysis Supports Existing Guidelines

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

A Synthesis of the Global Literature on TAVR Cost-effectiveness

Cost-Effectiveness of Catheter-Based Renal Denervation in Severe Treatment Resistant Hypertension

Cost-Effectiveness Considerations for Mild and Moderate Hypertension

Designation as ‘Unfit for Open Repair’ Predicts Worse EVAR Outcomes

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

FAME 2: FFR-Guided PCI ‘Economically Attractive’ vs. Medical Therapy Alone

Ambulatory EVAR an Option for One-Third of AAA Patients

Cost-Effectiveness of PCI in Patients with Stable Coronary Disease and Abnormal Fractional Flow Reserve (FFR)

Oral Sirolimus Appears to Augment Efficacy of BMS

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

COURAGE: Medical Therapy ‘Crossovers’ Have More Symptoms, not More Hard Events

European TAVR Usage Tied to Economics, Reimbursement

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

Cost-effectiveness of Surgical AVR vs. TAVR Using Registry Data

TAVR Cost-effectiveness and Reimbursement: A Global Gordian Knot

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content